Articles

Pharma Pulse 5/5/25: Deerfield Secures More than $600 Million for Next Biotech Venture Fund; What is The Hardest Job in Biopharma? 

A multi-national study reveals over half of older adults in several European countries are prescribed five or more medications—spotlighting the urgent need for better data-driven prescribing strategies.

Addressing Polypharmacy Challenges in Europe with Real World Evidence

The Zensights Federated Healthcare Advisory Panel explores how shifting global dynamics are reshaping access and strategic planning across the healthcare system.

 Asembia 2025: What Pharma Leaders Must Know About Tariffs, Supply Chains, and Policy Changes

. He can be reached at nsaraceno@mjhlifesciences.com.

Subject matter experts share the challenges that patients face in terms of medication affordability, along with the role that specialty pharmacies can play in helping to tackle these issues.

Asembia 2025: The Cost of Care for Patients

Videos

Will Pih, co-founder, Two Labs, explains how specialty pharmacies and manufacturers are adapting to financial pressures in rare disease care through patient-centric services, hub innovation, and hybrid technology models.

Asembia 2025: How Specialty Pharmacies Are Evolving to Support Rare Conditions

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

Asembia 2025: Rethinking the Drug Distribution Process

A seminar shares key observations and learnings from the first round of direct price negotiations.

Asembia 2025: Understanding the Inflation Reduction Act

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.

Asembia 2025: Rare Disease Therapies Drive Shift in Drug Development Focus

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase of growth and efficiency in specialty pharmacy.

News